BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De broe M, Kajbaf F, Lalau J. Renoprotective Effects of Metformin. Nephron 2018;138:261-74. [DOI: 10.1159/000481951] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol 2019;234:8286-94. [PMID: 30417367 DOI: 10.1002/jcp.27699] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
2 Drzewoski J, Hanefeld M. The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. Pharmaceuticals (Basel) 2021;14:122. [PMID: 33562458 DOI: 10.3390/ph14020122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
3 Sciannimanico S, Grimaldi F, Vescini F, De Pergola G, Iacoviello M, Licchelli B, Guastamacchia E, Giagulli VA, Triggiani V. Metformin: Up to Date. Endocr Metab Immune Disord Drug Targets 2020;20:172-81. [PMID: 31670618 DOI: 10.2174/1871530319666190507125847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Nath M, Bhattacharjee K, Choudhury Y. Pleiotropic effects of anti-diabetic drugs: A comprehensive review. Eur J Pharmacol 2020;884:173349. [PMID: 32650008 DOI: 10.1016/j.ejphar.2020.173349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Grissi M, Boudot C, Assem M, Candellier A, Lando M, Poirot-Leclercq S, Boullier A, Bennis Y, Lenglet G, Avondo C, Lalau JD, Choukroun G, Massy ZA, Kamel S, Chillon JM, Hénaut L. Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease. Sci Rep 2021;11:7464. [PMID: 33811249 DOI: 10.1038/s41598-021-86905-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Scheen AJ. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes Metab. 2019;45:110-121. [PMID: 30477733 DOI: 10.1016/j.diabet.2018.10.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
7 Luetić M, Kretzschmar G, Grobe M, Jerčić L, Bota I, Ivić V, Balog M, Zjalić M, Vitlov Uljević M, Heffer M, Gaspar R, Tabi T, Vukojević K, Vari SG, Filipović N. Sex-specific effects of metformin and liraglutide on renal pathology and expression of connexin 45 and pannexin 1 following long-term high-fat high-sugar diet. Acta Histochem 2021;123:151817. [PMID: 34808525 DOI: 10.1016/j.acthis.2021.151817] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lee MC, Lee CH, Chang LY, Chang CH, Zhang JF, Lee MR, Wang JY, Chen SM. Association of Metformin Use With End-Stage Renal Disease in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study Under the Pay-for-Performance Program. J Clin Pharmacol 2019;59:1443-52. [PMID: 31163098 DOI: 10.1002/jcph.1452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mbara KC, Mofo Mato PE, Driver C, Nzuza S, Mkhombo NT, Gcwensa SK, Mcobothi EN, Owira PM. Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. Eur J Pharmacol 2021;898:173934. [PMID: 33609563 DOI: 10.1016/j.ejphar.2021.173934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Meligi NM, Dyab AKF, Paunov VN. Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. Pharmaceutics 2021;13:1048. [PMID: 34371742 DOI: 10.3390/pharmaceutics13071048] [Reference Citation Analysis]
11 Meshkani SE, Mahdian D, Abbaszadeh-Goudarzi K, Abroudi M, Dadashizadeh G, Lalau JD, De Broe ME, Hosseinzadeh H. Metformin as a protective agent against natural or chemical toxicities: a comprehensive review on drug repositioning. J Endocrinol Invest 2020;43:1-19. [PMID: 31098946 DOI: 10.1007/s40618-019-01060-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Lee KA, Jin HY, Kim YJ, Kim SS, Cho EH, Park TS. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study. Medicine (Baltimore) 2022;101:e28823. [PMID: 35212277 DOI: 10.1097/MD.0000000000028823] [Reference Citation Analysis]
13 Neven E, Vervaet B, Brand K, Gottwald-hostalek U, Opdebeeck B, De Maré A, Verhulst A, Lalau J, Kamel S, De Broe ME, D’haese PC. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney International 2018;94:102-13. [DOI: 10.1016/j.kint.2018.01.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
14 Wahba NS, Ghareib SA, Abdel-Ghany RH, Abdel-Aal M, Alsemeh AE. Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition. Can J Physiol Pharmacol 2021;99:685-97. [PMID: 33108744 DOI: 10.1139/cjpp-2020-0435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ponticelli C, Favi E, Ferraresso M. New-Onset Diabetes after Kidney Transplantation. Medicina (Kaunas). 2021;57:250. [PMID: 33800138 DOI: 10.3390/medicina57030250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lalau JD, Al-Salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin M, Allix I, Amadou C, Bourron O, Duriez T, Gautier JF, Dutour A, Gonfroy C, Gouet D, Joubert M, Julier I, Larger E, Marchand L, Marre M, Meyer L, Olivier F, Prevost G, Quiniou P, Raffaitin-Cardin C, Roussel R, Saulnier PJ, Seret-Begue D, Thivolet C, Vatier C, Desailloud R, Wargny M, Gourdy P, Cariou B; CORONADO investigators. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab 2020;47:101216. [PMID: 33309936 DOI: 10.1016/j.diabet.2020.101216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
17 Wahba NS, Abdel-Ghany RH, Ghareib SA, Abdel-Aal M, Alsemeh AE, Sabry D. Vitamin D3 potentiates the nephroprotective effects of vildagliptin-metformin combination in a rat model of metabolic syndrome. Fundam Clin Pharmacol 2021. [PMID: 34453360 DOI: 10.1111/fcp.12721] [Reference Citation Analysis]
18 Huijink TM, Venema LH, Posma RA, de Vries NJ, Westerkamp AC, Ottens PJ, Touw DJ, Nijsten MW, Leuvenink HGD. Metformin Preconditioning and Postconditioning to Reduce Ischemia Reperfusion Injury in an Isolated Ex Vivo Rat and Porcine Kidney Normothermic Machine Perfusion Model. Clin Transl Sci 2021;14:222-30. [PMID: 32702185 DOI: 10.1111/cts.12846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Franzin R, Stasi A, Fiorentino M, Simone S, Oberbauer R, Castellano G, Gesualdo L. Renal Delivery of Pharmacologic Agents During Machine Perfusion to Prevent Ischaemia-Reperfusion Injury: From Murine Model to Clinical Trials. Front Immunol 2021;12:673562. [PMID: 34295329 DOI: 10.3389/fimmu.2021.673562] [Reference Citation Analysis]
20 Sunjaya AP, Sunjaya AF. Targeting ageing and preventing organ degeneration with metformin. Diabetes & Metabolism 2021;47:101203. [DOI: 10.1016/j.diabet.2020.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Jaikumkao K, Pongchaidecha A, Chueakula N, Thongnak L, Wanchai K, Chatsudthipong V, Chattipakorn N, Lungkaphin A. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2021-2033. [PMID: 29572114 DOI: 10.1016/j.bbadis.2018.03.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
22 Chung S, Kim GH. Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside. Life (Basel) 2021;11:389. [PMID: 33923115 DOI: 10.3390/life11050389] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol M. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis 2021:S0272-6386(21)00790-3. [PMID: 34391872 DOI: 10.1053/j.ajkd.2021.06.026] [Reference Citation Analysis]
24 Hasanvand A. The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases. Inflammopharmacology 2022. [PMID: 35419709 DOI: 10.1007/s10787-022-00980-6] [Reference Citation Analysis]
25 Yu Q, Zhu JJ, Liu WX. Effect of continuous use of metformin on kidney function in diabetes patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. BMC Cardiovasc Disord 2020;20:187. [PMID: 32316910 DOI: 10.1186/s12872-020-01474-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Giaccari A, Solini A, Frontoni S, Del Prato S. Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism? Diabetes Care 2021;44:647-54. [PMID: 33608326 DOI: 10.2337/dc20-1964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Nobakht N, Hanna RM, Al-Baghdadi M, Ameen KM, Arman F, Nobahkt E, Kamgar M, Rastogi A. Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review. Kidney Med 2020;2:196-208. [PMID: 32734239 DOI: 10.1016/j.xkme.2019.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tain YL, Hsu CN. AMP-Activated Protein Kinase as a Reprogramming Strategy for Hypertension and Kidney Disease of Developmental Origin. Int J Mol Sci 2018;19:E1744. [PMID: 29895790 DOI: 10.3390/ijms19061744] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
29 Bennis Y, Bodeau S, Batteux B, Gras-champel V, Masmoudi K, Maizel J, De Broe ME, Lalau J, Lemaire-hurtel A. A Study of Associations Between Plasma Metformin Concentration, Lactic Acidosis, and Mortality in an Emergency Hospitalization Context. Critical Care Medicine 2020;48:e1194-202. [DOI: 10.1097/ccm.0000000000004589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
30 Valiño-Rivas L, Cuarental L, Ceballos MI, Pintor-Chocano A, Perez-Gomez MV, Sanz AB, Ortiz A, Sanchez-Niño MD. Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis. Kidney Int 2022:S0085-2538(22)00210-1. [PMID: 35337892 DOI: 10.1016/j.kint.2022.02.028] [Reference Citation Analysis]
31 Zulpaite R, Miknevicius P, Leber B, Strupas K, Stiegler P, Schemmer P. Ex-vivo Kidney Machine Perfusion: Therapeutic Potential. Front Med (Lausanne) 2021;8:808719. [PMID: 35004787 DOI: 10.3389/fmed.2021.808719] [Reference Citation Analysis]